E. Hellstrôm-Lindberg

发表

Pan-cancer analysis of whole genomes

Steven J. M. Jones, Nuno A. Fonseca, Icgc, 2020, Nature.

Guideline-based indicators for adult patients with myelodysplastic syndromes.

D. Schwappach, D. Steensma, P. Fenaux, 2020, Blood advances.

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

M. Stratton, P. Campbell, P. Stephens, 2011, The New England journal of medicine.

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

M. Stratton, P. Campbell, S. O'meara, 2013, Blood.

Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

Bin Tean Teh, Andrew Menzies, Keiran Raine, 2014, eLife.

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

D. Swinkels, A. Stamatoullas, C. Craddock, 2020, Leukemia.

Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application.

P. Fenaux, D. Bowen, E. Hellstrôm-Lindberg, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

E. Estey, L. Silverman, G. Mufti, 2014, Leukemia research.

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM).

P. Campbell, M. Cazzola, D. Neuberg, 2020, Blood.

Progression in patients with low- and intermediatel-risk del(Sq) myelodysplastic syndromes

D. Neuberg, S. E. Jacobsen, L. Saft, 2017 .

A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome

S. Kajigaya, N. Young, R. Calado, 2014, BMC Medical Genetics.

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

R. Larson, H. Kantarjian, P. Fenaux, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.

E. Estey, P. Greenberg, C. Willman, 2000, Journal of Clinical Oncology.

Author's response to reviews Title:A mutation in H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome Authors:

S. Kajigaya, R. Calado, E. Hellstrôm-Lindberg, 2014 .

Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?

D. Bowen, E. Hellstrôm-Lindberg, E. Hellstrom-Lindberg, 2001, Leukemia research.

Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.

B. Johansson, L. Kjeldsen, B. Uggla, 2006, Haematologica.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

P. Campbell, M. Cazzola, D. Neuberg, 2020, Blood.

Patterns of somatic structural variation in human cancer genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature.

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature Communications.

L. Donehower, A. Langerød, L. Strong, 2017, Cancer research.

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.

Susan R. Wilson, P. Campbell, P. Woll, 2017, Cell reports.

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions

Kirsten R. McEwen, P. Campbell, A. Green, 2013, Clinical Epigenetics.

Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study

J. Byrd, G. Mufti, J. Bennett, 2012 .

Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors.

B. Zhivotovsky, B. Fadeel, R. Tehranchi, 2003, Blood.

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.

M. Cazzola, H. Deeg, P. Greenberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive molecular characterization of mitochondrial genomes in human cancers

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2017, bioRxiv.

Author Correction: Pan-cancer analysis of whole genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2023, Nature.

Sex differences in oncogenic mutational processes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2019, Nature Communications.